Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Sartore-Bianchi

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
Handbook of Experimental Pharmacology|April 7, 2017
Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Salvatore Siena
Cancer Cell|August 29, 2020
Breaking Barriers in HER2+ CancersSalvatore Siena, Silvia Marsoni, Andrea Sartore-Bianchi
ESMO Open|November 16, 2016
<i>NTRK</i> gene fusions as novel targets of cancer therapy across multiple tumour typesAlessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena
Cancer Treatment Reviews|November 20, 2016
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFRAndrea Sartore-Bianchi, Salvatore Siena, Giuseppe Tonini, et al.
Expert Review of Anticancer Therapy|August 1, 2012
New frontiers in therapeutic resistance in cancerAndrea Sartore-Bianchi, Mauro Delorenzi, Thérèse Gagnon-Kugler, et al.
Cancer Discovery|October 9, 2014
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolutionSandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, et al.
Journal of the National Cancer Institute|September 10, 2009
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerSalvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, et al.
Oncology Reports|September 18, 2004
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patientsAndrea Sartore-Bianchi, Alessandra Soriani, Raffaella Mattioni, et al.
Expert Review of Anticancer Therapy|February 25, 2014
Regorafenib in metastatic colorectal cancerAndrea Sartore-Bianchi, Annalisa Zeppellini, Alessio Amatu, et al.
Lung Cancer (Amsterdam, Netherlands)|October 26, 2002
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta, Vittoria Rizzo, Matteo Zimatore, et al.
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
Handbook of Experimental Pharmacology|April 7, 2017
Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Salvatore Siena
Cancer Cell|August 29, 2020
Breaking Barriers in HER2+ CancersSalvatore Siena, Silvia Marsoni, Andrea Sartore-Bianchi
ESMO Open|November 16, 2016
<i>NTRK</i> gene fusions as novel targets of cancer therapy across multiple tumour typesAlessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena
Cancer Treatment Reviews|November 20, 2016
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFRAndrea Sartore-Bianchi, Salvatore Siena, Giuseppe Tonini, et al.
Expert Review of Anticancer Therapy|August 1, 2012
New frontiers in therapeutic resistance in cancerAndrea Sartore-Bianchi, Mauro Delorenzi, Thérèse Gagnon-Kugler, et al.
Cancer Discovery|October 9, 2014
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolutionSandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, et al.
Journal of the National Cancer Institute|September 10, 2009
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerSalvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, et al.
Oncology Reports|September 18, 2004
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patientsAndrea Sartore-Bianchi, Alessandra Soriani, Raffaella Mattioni, et al.
Expert Review of Anticancer Therapy|February 25, 2014
Regorafenib in metastatic colorectal cancerAndrea Sartore-Bianchi, Annalisa Zeppellini, Alessio Amatu, et al.
Lung Cancer (Amsterdam, Netherlands)|October 26, 2002
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta, Vittoria Rizzo, Matteo Zimatore, et al.
Pageof 17